Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting

onday, December 9, 5:00 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 687
  • Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

    • Dr. Neha Korde, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 3:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Treatment Options for Newly Diagnosed Multiple Myeloma Patients
    • Abstract # 538

    Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)

    • Dr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute, National Institutes of Health
    • Monday, December 9, 7:30 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia
    • Abstract # 762

    Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma

    • Dr. Jatin Shah, The University of Texas MD Anderson Cancer Center
    • Monday, December 9, 5:45 pm CT, 393-394
    • Oral presentation: Myeloma: Therapy, excluding Transplantation II
    • Abstract # 690

    Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based the

    SOURCE Onyx Pharmaceuticals, Inc.; Amgen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
    2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
    3. Amgen Announces 2012 First Quarter Dividend
    4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
    5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
    6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
    7. Amgen to Acquire Micromet
    8. Amgen to Present at the Leerink Swann Global Healthcare Conference
    9. Amgen Announces 2012 Third Quarter Dividend
    10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
    11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
    Post Your Comments:
    (Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
    (Date:10/8/2015)... ... October 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: ... develop and commercialize intellectual property rights belonging to The University of British Columbia ... affords exclusive worldwide rights to intellectual property based on use of the ProMIS™ ...
    (Date:10/7/2015)... Worth, Texas (PRWEB) , ... October 07, 2015 ... ... Cell Institute ( ) will present a public educational seminar on the ... on Saturday, October 10th from 1:00 pm – 3:00 pm at the Hilton ...
    (Date:10/7/2015)... Oct. 7, 2015   VWR (NASDAQ: ... laboratory products, services and solutions, announced today that ... specialty solvent company that performs high volume purification ... enhance VWR,s growing laboratory and production chemical manufacturing ... manufacturing customers. Manuel Brocke-Benz , President ...
    Breaking Biology Technology:
    ... November 13 Axelar AB today announced that,promising ... concerning their,lead anticancer product AXL1717, an insulin-like growth ... at the AACR-NCI-EORTC,International Conference on Molecular Targets and ... being conducted in Sweden,on advanced-stage cancer patients with ...
    ... , SOUTH SAN FRANCSICO, Calif., Nov. 12 ... encompassing a completely novel mechanism for generating massive ... sequences. The technology platform is referred to ... issued in both the United States (#7,585,957) and ...
    ... 12 Neogen Corporation (Nasdaq: NEOG ) has been selected ... Friday, Nov. 13, to celebrate Neogen,s 20th anniversary of being listed ... on behalf of the countless many who have made Neogen,s success ... has come a long way in the 20 years since our ...
    Cached Biology Technology:
    (Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
    (Date:9/10/2015)... 10, 2015 Report Details ... Selling Opportunities and Revenue Prospects to Help You ... biologics, especially new drug classes? Get the latest ... with exclusive market data and industry knowledge, benefitting ... results, opportunities and sales predictions. Visiongain,s new ...
    (Date:9/10/2015)... ATLANTA , Sept. 10, 2015 ... Cleveland Clinic Wellness to create an interactive, image-based ... self-service health and wellness kiosk.  The unique assessment ... Age"— a number that suggests an individual,s biological ... biometric values as measured by the kiosk. ...
    Breaking Biology News(10 mins):
    ... too much water, including sports drinks, when exercising, ... in prolonged types of endurance exercise at risk ... who study disorders of water metabolism. Such exercise ... This serious condition, known as exercise-induced hyponatremia (EAH), ...
    ... A new, fast and inexpensive way to mutate genes and ... of Utah geneticists. They tested the method by mutating a ... and limbs in the mutant mouse on the left, compared ... The new method promises to speed efforts to learn more ...
    ... nanoparticle made in a laboratory at the University of ... device for treating glaucoma, an eye disease that can ... “The nanoparticle can safely get past the blood-brain barrier ... said Sudipta Seal, an engineering professor with appointments in ...
    Cached Biology News:
    Recalibration of HL-2000-CAL products...
    Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
    Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
    Biology Products: